Why the study?
DM and PAD share pathophysiological pathways, and emerging data on agents targeting these pathways along with the pleiotropic effects of novel glucose-lowering drugs warrant summary.
Design
Review
Authors
Loading...
May inform comorbid DM-PAD management; leaves open confirmation of pleiotropic benefits in randomized trials.
This review highlights emerging medical and interventional approaches, including novel glucose-lowering drugs, for managing peripheral artery disease in patients with diabetes mellitus.
Demarchi et al. (2020) studied this question.